Skip Navigation LinksHome > March/April 2009 - Volume 15 - Issue 2 > Salvage Therapy for Hodgkin’s Lymphoma
Cancer Journal:
doi: 10.1097/PPO.0b013e3181a1438a
Special Issue on Hodgkin's Lymphoma: Original Article

Salvage Therapy for Hodgkin’s Lymphoma

Quddus, Fahd MD; Armitage, James O. MD

Collapse Box

Abstract

Hodgkin’s lymphoma (HL) is a clonal lymphoid malignancy that affects over 7000 patients in the United States annually. The disease remains one of the great success stories in the recent history of cancer treatment. More than 80% of HL patients will be expected to be long-term survivors because of recent advances in radiation therapy and combined chemotherapy. However, for the subset of patients who relapse after initial therapy, HL remains a challenging disease. Indeed, for patients who relapse after salvage high-dose chemotherapy and autologous stem cell transplant, effective therapeutic options remain limited, and further new therapies are warranted. This article provides a review of the current literature regarding salvage therapy for HL.

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.